Stock market analysts have maintained 'buy' rating on Ranbaxy Laboratories Ltd with an intraday target of Rs 525.

According to them, investors can buy the stock with a strict stop loss of Rs 507.

If the stock markets remain on the positive path then the stock price will hit a target above Rs 527.

Shares of the company, on Monday (Dec 14), closed at Rs 517.05 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 519.90 and a low of Rs 133.15 on BSE.

Pharmaceutical major Ranbaxy announced that it will roll out a generic edition of the urinary disorder treatment, Flomax, by the coming year (2010).

Mr. Omesh Sethi, CFO of the company said the company is doing well and they are eyeing hefty revenue from Indian as well as international markets by the next financial year.

Ranbaxy Laboratories on Dec 08 stated that it was selling its 50% equity stake in its Japanese JV Nihon Pharmaceutical Industry to its associate Nippon Chemiphar.

Even though Ranbaxy didn't offer any amount, global media reports valued the 50% equity stake at $18 million.

Ranbaxy has become a division of another Japanese company Daiichi Sankyo that now hold 64% in the Indian company.

Presently, Indian company supplies around 7 drugs to the joint venture that will be finished slowly in order to allow a smooth transition.

The development is likely to pave the mode for Daiichi Sankyo and Ranbaxy to sell their generics in the Japanese market on their own.